MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Pancreas, Pancreatic
Verastem Oncology, Inc. (NASDAQ:VSTM)*
Organization & Developments: VeraStem
Parents
Verastem Oncology, Inc. (NASDAQ:VSTM)*
Children
*Its programs target the focal adhesion kinase (FAK) and the phosphoinositide-3-kinase (PI3K)/mTOR signaling pathways.
*Organization & Developments: VeraStem (2011-2018)
*The company is focused on discovering and developing drugs for the treatment of cancer, DEVELOPS SMALL MOLECULE DRUGS TARGETING CANCER STEM CELLS ALONG WITH PROPRIETARY COMPANION DIAGNOSTICS.
2019: VA_65--Contract Award Effective Date 03/15/2019-03/14/2024 Verastem, Inc., D.B.A. Verastem Oncology
2019: Verastem (VSTM) Reports Q1 Loss, Lags Revenue Estimates
2019: Verastem: A Speculative Buy_seekingalpha.com
2019: Verastem: Copiktra To Power Turnaround Prospect - Verastem, Inc. (NASDAQ:VSTM)
2019: Verastem: Ready To Rebound?_seekingalpha.com
2020: The Play On Verastem
2020: Verastem Has Strong Points, But The Long-Term Case Is Not Compelling_seekingalpha.com
2020: Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766
2020: Verastem Oncology Announces New Strategic Direction to Advance Its Clinical Development Programs
2020: Verastem: Revisiting This $2 Oncology Concern
2021: Verastem: New Assets, New Indications
2022: Verastem: Moving Forward_ seekingalpha.com
2023: Verastem: Potential Accelerated Approval Filing In H1 2024
2024: Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
2024: Verastem: A Shocking Drop On 'Positive' Data (Maintain Buy)
2024: Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade
2024: Verastem: Other Catalysts In 2024 Beyond NDA Rolling Submission Of Defactinib
2024: Verastem: Preparing For Upcoming Catalysts
2025: Verastem soars on FDA priority review for avutometinib
2025: Verastem: BLA Acceptance Puts Key Goals In Sight_ seekingalpha.com
2025: Verastem: Planning The PDUFA Run-Up_seekingalpha.com
2025: Verastem: Upcoming PDUFA, But I Remain Cautious
Jumps
*Key People: VeraStem
Finance & Acquisitions: Verastem